Article

Rheumatology Network's Top 5: September 10, 2022

Author(s):

Lana Pine

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2022.

Ustekinumab Quickly, Effectively Treats Patients with Active PsA

In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.

Rheumatology Month in Review: August 2022

Rheumatology Network's month in review spotlights the most popular content from the past month.

Litifilimab Superior to Placebo in Patients with Cutaneous Lupus Erythematosus

“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”

Anxiety, Depression Highly Prevalent in Patients with Lupus Nephritis

"Lupus nephritis (LN) patients might suffer from mental disorders which further prolong the LN treatment duration and affect patients' quality of life.”

Kinesiophobia Negatively Impacts Functional Task Performance in JIA

“Kinesiophobia plays a major role in the onset, persistence, and exacerbation of chronic disability in a variety of musculoskeletal disorders."

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Related Content
Orrin Troum, MD, clinical professor of medicine, Keck School of Medicine, University of Southern California, and director, clinical rheumatology research, Providence St John's Hospital, Santa Monica, California
November 22nd 2024

Shortened Pegloticase Infusions Feasible for Uncontrolled Gout, Reduces Treatment Burden

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Søren Andrea Just, MD, PhD, associate professor, University of Southern Denmark, and Odense University Hospital – Svendborg.
November 21st 2024

AI Assessments, Robotics Perform to Rheumatologist Levels in Joint Assessment

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Megan Clowse, MD, MPH, Associate Professor of Medicine, Associate Professor in Obstetrics and Gynecology, and Associate Professor in Population Health Sciences, and Chief of the Division of Rheumatology and Immunology, Duke University School of Medicine
November 19th 2024

DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE

Victoria Johnson
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
November 19th 2024

Vagus Nerve Stimulation Yields Responses in Refractory Rheumatoid Arthritis

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.